Compare Dover Corp (DOV) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs Merck & Co., Inc. — how do they compare? Dover Corp trades at $207.57 (market cap $28.02B), while Merck & Co., Inc. trades at $133.26 (market cap $327.94B). The key difference: Merck & Co., Inc. is far larger — about 11.7× Dover Corp's market cap, and Merck & Co., Inc. pays the higher dividend (2.56%). Which is the better fit depends on your goals.
| DOV | MRK | |
|---|---|---|
Market Cap | $28.02B | $327.94B |
Sector | Industrials | Health |
52-Week High | $233.31 | $132.93 |
52-Week Low | $161.16 | $77.60 |
Enterprise Value | $29.53B | $374.70B |
Dividend Yield | 1.01% | 2.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dover Corporation (DOV) trades at $208.07, down 0.97% on the day, with strong analyst support showing 19 buy ratings and a $232.33 consensus price target. The company demonstrates solid fundamentals with consistent earnings beats, a 13.48% net income margin, and recent dividend increases. Technical indicators show a bearish short-term signal despite neutral oscillators, with key support at $205.
DOV presents a compelling investment case with strong profitability, dividend growth, and raised 2026 guidance, though near-term technical weakness and acquisition integration risks warrant monitoring. The stock offers approximately 11.7% upside to analyst targets with no sell ratings among 28 covering firms.
Merck (MRK) trades at $130.45, down 0.34% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01B in 2025, and net income reached $18.25B. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples and competitive pressures. Analysts maintain a bullish consensus with a $140.58 price target, suggesting potential upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
